{"disease":{"id":"following-complete-or-partial-response-to-platinum-based-chemotherapy","name":"following complete or partial response to platinum based chemotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03534453","title":"Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}